JP2021522784A - 合成キメラワクシニアウイルス - Google Patents

合成キメラワクシニアウイルス Download PDF

Info

Publication number
JP2021522784A
JP2021522784A JP2020560920A JP2020560920A JP2021522784A JP 2021522784 A JP2021522784 A JP 2021522784A JP 2020560920 A JP2020560920 A JP 2020560920A JP 2020560920 A JP2020560920 A JP 2020560920A JP 2021522784 A JP2021522784 A JP 2021522784A
Authority
JP
Japan
Prior art keywords
scvacv
virus
genome
seq
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020560920A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522784A5 (https=
Inventor
デイビッド エバンス，
デイビッド エバンス，
ライアン ノイス，
ライアン ノイス，
セス レーダーマン，
セス レーダーマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2021522784A publication Critical patent/JP2021522784A/ja
Publication of JP2021522784A5 publication Critical patent/JP2021522784A5/ja
Priority to JP2024028557A priority Critical patent/JP2024051112A/ja
Priority to JP2025151400A priority patent/JP2025178289A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020560920A 2018-05-02 2019-05-02 合成キメラワクシニアウイルス Withdrawn JP2021522784A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024028557A JP2024051112A (ja) 2018-05-02 2024-02-28 合成キメラワクシニアウイルス
JP2025151400A JP2025178289A (ja) 2018-05-02 2025-09-11 合成キメラワクシニアウイルス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862665973P 2018-05-02 2018-05-02
US62/665,973 2018-05-02
PCT/US2019/030486 WO2019213452A1 (en) 2018-05-02 2019-05-02 Synthetic chimeric vaccinia virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024028557A Division JP2024051112A (ja) 2018-05-02 2024-02-28 合成キメラワクシニアウイルス

Publications (2)

Publication Number Publication Date
JP2021522784A true JP2021522784A (ja) 2021-09-02
JP2021522784A5 JP2021522784A5 (https=) 2022-05-12

Family

ID=68386164

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020560920A Withdrawn JP2021522784A (ja) 2018-05-02 2019-05-02 合成キメラワクシニアウイルス
JP2024028557A Pending JP2024051112A (ja) 2018-05-02 2024-02-28 合成キメラワクシニアウイルス
JP2025151400A Pending JP2025178289A (ja) 2018-05-02 2025-09-11 合成キメラワクシニアウイルス

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024028557A Pending JP2024051112A (ja) 2018-05-02 2024-02-28 合成キメラワクシニアウイルス
JP2025151400A Pending JP2025178289A (ja) 2018-05-02 2025-09-11 合成キメラワクシニアウイルス

Country Status (12)

Country Link
US (1) US12529036B2 (https=)
EP (1) EP3788142A4 (https=)
JP (3) JP2021522784A (https=)
CN (2) CN121320271A (https=)
AR (1) AR115069A1 (https=)
AU (1) AU2019262149B2 (https=)
BR (1) BR112020022181A2 (https=)
CA (1) CA3099330A1 (https=)
MX (1) MX2020011586A (https=)
SG (1) SG11202010272PA (https=)
TW (1) TW201946651A (https=)
WO (1) WO2019213452A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019535311A (ja) 2016-11-02 2019-12-12 デイビッド エバンス， 合成キメラポックスウイルス
EP3703723A4 (en) 2017-10-31 2021-12-15 KaliVir Immunotherapeutics, Inc. ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION
EP3788142A4 (en) 2018-05-02 2022-04-27 Tonix Pharma Holdings Limited SYNTHETIC CHIMERIC VACCINE VIRUS
CA3168836A1 (en) * 2020-02-03 2021-08-12 City Of Hope Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
KR20220165731A (ko) * 2020-02-26 2022-12-15 토닉스 파마 리미티드 Sars-cov-2 바이러스에 대한 재조합 폭스바이러스 기반 백신
EP4153228A4 (en) * 2020-05-17 2024-07-10 City of Hope CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
TW202227621A (zh) 2020-11-19 2022-07-16 美商凱立凡爾免疫治療股份有限公司 重塑腫瘤微環境的溶瘤免疫療法
JP2024505274A (ja) 2021-02-02 2024-02-05 ゲオバックス インコーポレイテッド ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト
BR112023022681A2 (pt) 2021-04-30 2024-01-23 Kalivir Immunotherapeutics Inc Vírus oncolíticos para expressão modificada de mhc
WO2023168286A1 (en) 2022-03-01 2023-09-07 Tonix Pharmaceuticals Holding Corp. Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
CN116042656A (zh) * 2022-11-25 2023-05-02 中山大学附属第七医院(深圳) 一种猴痘病毒mRNA疫苗及其制备方法与用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014034A1 (en) * 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus
JP2019535311A (ja) * 2016-11-02 2019-12-12 デイビッド エバンス， 合成キメラポックスウイルス
JP2021522789A (ja) * 2018-05-02 2021-09-02 トニックス ファーマ ホールディングス リミテッド 合成キメラワクシニアウイルスを含む幹細胞およびそれらを使用する方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787577A (en) 1953-12-01 1957-04-02 Lilly Co Eli Stable smallpox vaccine
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6723325B1 (en) 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
US8541003B2 (en) 2003-06-20 2013-09-24 Protein Sciences Corporation Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
WO2005028634A2 (en) 2003-09-18 2005-03-31 Emory University Improved mva vaccines
WO2005103259A1 (en) 2004-04-26 2005-11-03 University Health Network Sars-cov nucleocapsid protein epitopes and uses thereof
JPWO2006022215A1 (ja) 2004-08-23 2008-05-08 財団法人ヒューマンサイエンス振興財団 ＳＡＲＳ−コロナウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用
CN101020055B (zh) 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 基于复制型痘苗病毒载体的sars疫苗
EP2097517B1 (en) 2006-10-16 2014-06-04 Genelux Corporation Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
US8795667B2 (en) 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
ES2733211T3 (es) * 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
FI20115914L (fi) * 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
WO2014166084A1 (en) * 2013-04-10 2014-10-16 Totbiopharm Shanghai R & D Center Mutant vaccinia virus strains, uses thereof and method of producing the same
EP3045181B1 (en) 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
CN108135996B (zh) 2015-08-11 2022-06-21 卡利迪生物治疗有限公司 用以癌症治疗的天花疫苗
WO2017047089A1 (en) 2015-09-16 2017-03-23 Shin Nippon Biomedical Laboratories, Ltd. Vaccine compositions
AU2017332367B2 (en) 2016-09-21 2021-12-23 Stephen H. Thorne High mobility group box i mutant
ES2702618B2 (es) 2017-09-04 2019-10-31 Inst De Salud Carlos Iii Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica.
EP3788142A4 (en) 2018-05-02 2022-04-27 Tonix Pharma Holdings Limited SYNTHETIC CHIMERIC VACCINE VIRUS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014034A1 (en) * 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus
JP2019535311A (ja) * 2016-11-02 2019-12-12 デイビッド エバンス， 合成キメラポックスウイルス
JP2021522789A (ja) * 2018-05-02 2021-09-02 トニックス ファーマ ホールディングス リミテッド 合成キメラワクシニアウイルスを含む幹細胞およびそれらを使用する方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J VIROL, 2003 JUL, vol. 77, no. 13, JPN6023018907, pages 7281 - 7290, ISSN: 0005184577 *
METHODS MOL BIOL, 2004, vol. 269, JPN6023018908, pages 51 - 64, ISSN: 0005056677 *
PLOS ONE, 2018 JAN 19, vol. 13, no. 1, JPN6023018906, pages 0188453 - 1, ISSN: 0005184576 *

Also Published As

Publication number Publication date
AU2019262149A1 (en) 2020-11-12
US12529036B2 (en) 2026-01-20
JP2025178289A (ja) 2025-12-05
AR115069A1 (es) 2020-11-25
US20210230560A1 (en) 2021-07-29
SG11202010272PA (en) 2020-11-27
MX2020011586A (es) 2020-12-07
AU2019262149B2 (en) 2025-09-11
TW201946651A (zh) 2019-12-16
EP3788142A4 (en) 2022-04-27
EP3788142A1 (en) 2021-03-10
CN112543806A (zh) 2021-03-23
WO2019213452A9 (en) 2021-01-14
WO2019213452A1 (en) 2019-11-07
CN112543806B (zh) 2025-06-06
CA3099330A1 (en) 2019-11-07
JP2024051112A (ja) 2024-04-10
BR112020022181A2 (pt) 2021-02-09
CN121320271A (zh) 2026-01-13

Similar Documents

Publication Publication Date Title
US12529036B2 (en) Synthetic chimeric vaccinia virus
US12365879B2 (en) Synthetic chimeric poxviruses
EP4110386A1 (en) Recombinant poxvirus based vaccine against sars-cov-2 virus
US20210236619A1 (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
HK40014109B (zh) 合成嵌合痘病毒
HK40014109A (en) Synthetic chimeric poxviruses
WO2023168286A1 (en) Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
Holley Mechanistic Constraints on the Formation of Virion Morphotypes in Vaccinia Virus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240228

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240423

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240430